Prelude Therapeutics at Chardan conference: bet on selective degraders

On Tuesday, 20 October 2026, Prelude Therapeutics (PRLD) utilized Chardan's 10th Annual Healthcare Conference to reveal a more focused pipeline, centered around three clinically validated targets and a focus on selective protein degradation. Management acknowledged that this strategic shift, undertaken roughly a year ago, necessitates further clinical validation.

Prelude's primary targets include JAK2 JH2, KAT6A degrader, and mCALR. The JAK2 JH2 program entered clinical trials in Q2 2026, while KAT6A has secured IND clearance and is expected to start enrollment soon. The company believes its selective KAT6A degrader could offer superior activity and tolerability compared to dual KAT6A and KAT6B inhibitors developed by competitors.

A potential $100 million payment from Incyte, contingent on exercising the mCALR option in the first half of 2027, is a significant near-term funding milestone. Prelude's CFO, Bryant Lim, emphasized that the pivot was centered on clinically validated targets, stating, "Each of them are clinically validated targets, and that really formed the basis of our pivot."

The company aims to employ a more selective approach than many rivals, particularly in the KAT6A space, where numerous firms are developing dual KAT6A and KAT6B inhibitors. Prelude highlighted the advantages of selective degradation, suggesting it could lead to stronger biology and better tolerability. The company provided an update on its main programs: JAK2 JH2, which entered clinical trials in Q2 2026; KAT6A degrader, which received IND clearance with enrollment anticipated to commence shortly; and mCALR, which remains part of the strategic plan with an option decision from Incyte that could impact funding.

For the KAT6A program, Prelude explained that the clinical protocol focuses on monotherapy activity, safety, and early combination use with fulvestrant. Preclinical data demonstrated complete tumor regressions in patient-derived xenograft and cell-derived xenograft models at doses achieving selective KAT6A degradation. The degrader approach reportedly showed better activity than inhibitor-based approaches, which, according to Prelude, often resulted in tumor stasis rather than regression.

The company also noted that the KAT6A degrader could potentially be combined with standard-of-care agents, such as CDK4/6 inhibitors, SERDs, and PI3K inhibitors, across multiple mutations. This combination potential is crucial to the company's strategy of advancing the drug into earlier treatment settings. Chief Scientific Officer Peggy Scherle explained that KAT6A is amplified and overexpressed in ER-positive breast cancer, contributing to estrogen signaling, Myc regulation, and cell-cycle progression.

She stated that the company's selective degrader may avoid the neutropenia observed with dual KAT6A and KAT6B inhibitors. Scherle compared Prelude's approach to Pfizer's KAT6A and KAT6B inhibitor data, noting that monotherapy response rates with the inhibitor-based approach were around 10%, while combination use with fulvestrant yielded response rates in the mid-30% range and progression-free survival of 10 to 11 months.

Prelude's approach, according to Scherle, differs in three key aspects: sparing KAT6B to potentially reduce neutropenia, achieving over 1,000-fold selectivity by utilizing the full ternary complex, and potentially creating deeper biology through protein complex disassembly rather than mere inhibition. By sparing KAT6B, the company aims to enhance the degrader's profile.

Management also discussed Prelude's JAK2 V617F program, which targets myeloproliferative neoplasms using a structure-based design approach to target a deep pocket containing the V617F mutation. The company achieved about 10-fold selectivity for mutant JAK2 versus wild-type JAK2, with pharmacokinetic properties supporting selective targeting.

Prelude highlighted that its selectivity testing, based on panels of wild-type and mutant cell lines, provides a more realistic view of patient variability compared to cherry-picked comparisons. The company contrasted its selectivity data with figures from competitors like Incyte (5-fold), Cogent (170-fold), and Eli Lilly (500-fold), acknowledging differences in assay methods.

Prelude did not disclose revenue, operating expenses, or cash balance figures during the presentation, focusing instead on future milestone-based funding. The main funding item discussed was a potential $100 million payment from Incyte, contingent on exercising the mCALR option in the first half of 2027.